Changes in the Oral Treatment of Psoriasis at Fukuoka University

Yamaguchi, Kazuki; Ohga, Yasunori; Kunimi, Yuka; Shibayama, Yuki; Naito, Reiko; Koga, Monji; Ito, Keisuke; Imafuku, Shinichi

doi:10.2336/nishinihonhifu.81.316

Cited by 1 publication

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from Group 1 were obtained from our previous study. 18 The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine at Fukuoka University (approval no. U19-03-004).…”

Section: Methodsmentioning

confidence: 99%

“…Patients treated with upadacitinib were not enrolled because all these patients were on clinical trials. Data from Group 1 were obtained from our previous study 18 . The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine at Fukuoka University (approval no.…”

Section: Methodsmentioning

confidence: 99%

“…At Fukuoka University Hospital, all patients with psoriasis are registered in the Fukuoka University Psoriasis Registry 13–17 . To record the treatment trend before the approval of apremilast, we investigated the use of oral drugs for treating patients with psoriasis listed in our registry from 2010 to 2016 18 . Our previous study revealed that cyclosporine was the most frequently prescribed small molecule and has been used for a relatively long time, even though several biologics were already available.…”

Section: Introductionmentioning

confidence: 99%

“…[13][14][15][16][17] To record the treatment trend before the approval of apremilast, we investigated the use of oral drugs for treating patients with psoriasis listed in our registry from 2010 to 2016. 18 Our previous study revealed that cyclosporine was the most frequently prescribed small molecule and has been used for a relatively long time, even though several biologics were already available. In the present study, we conducted another survey covering the period after apremilast became available in Japan (2017-2021) and compared the results with our previous data to measure the impact of apremilast.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Trends in prescriptions of oral medications for psoriasis: A single‐center retrospective study

Takano‐Kawasaki

Sato

Yamaguchi³

et al. 2022

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Systemic therapy for psoriasis has changed markedly with the advent of biologics. Various studies have provided real-world evidence of their efficacy, adverse reactions, and continuation rates.The development of oral anti-psoriatic drugs has been relatively slow, and conventional oral drugs have long been used. Etretinate was first approved for use in psoriasis in Japan in 1985, followed by cyclosporine in 1992. Methotrexate has been the most frequently used systemic treatment globally since the 1970s 1 ; however, it was approved for psoriasis in Japan only in 2019. Although effective, cyclosporine is not recommended for long-term continuous use because of its renal toxicity. 2,3 The unavailability of methotrexate has sometimes forced Japanese dermatologists to administer cyclosporine

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%